Pharma Journalist -

Vivet Therapeutics announced that it has recieved €37.5 million in a Series A financing round for advancement in developing gene therapies for treatment of rare inherited metabolic…
Read More...

BioPharmX announced that it achieved primary endpoint in its phase 2b clinical trial evaluating BPX-011. From the topline results for the study's primary endpoint, BioPharmX…
Read More...

CARsgen Therapeutics (CArsgen) announced the opening of CAR-T cell manufacturing facility in Shanghai to support CARsgen clinical programs. It is  China’s first CAR-T cell manufacturing…
Read More...

Cannabics Pharmaceutical has began a scientific collaboration with European lab working on circulating tumor cells (CTC) count and drug sensitivity tests for cancer patients. The…
Read More...

Swedish Orphan Biovitrum AB (Sobi) announced that it has appointed Guido Oelkers as New President and CEO who will be succeeding Geoffrey McDonough effectively from 22 May, 2017.…
Read More...

Concordian International announced that they have Itzhak Krinsky, PhD. and Francis (Frank) Perier, Jr. as members of Board of Directors. After this appointment the Board will…
Read More...

David Price has been appointed as CFO (Chief Financial Officer) of Concordia International. He will succeed Edward Borkowski and will be effective from May 15,2017. He will be reporting…
Read More...

Callery Corporation announced that it has appointed Dr. Harry Rathore as its Chief Executive Officer. Dr. Rathore holds a Ph.D. in Medicinal Chemistry from the Oregon State…
Read More...

Sandoz Canada announced the launch of Sandoz Olmesartan (olmesartan medoxomil), a generic version of OLMETEC, for the treatment of mild to moderate essential hypertension. This follows…
Read More...

Propanc Biopharma provided an update on the development of the GMP-compliant investigational medicinal product (IMP) manufacture of PRP for First-In-Human studies. PRP is a solution for…
Read More...